Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report)’s share price was up 5.6% on Monday. The company traded as high as GBX 700 and last traded at GBX 695. Approximately 19,073 shares traded hands during trading, a decline of 20% from the average daily volume of 23,988 shares. The stock had previously closed at GBX 658.
Hemogenyx Pharmaceuticals Trading Up 7.5%
The stock has a 50 day simple moving average of GBX 567.64 and a 200-day simple moving average of GBX 690.59. The company has a current ratio of 4.04, a quick ratio of 6.72 and a debt-to-equity ratio of 42.86. The firm has a market capitalization of £51.14 million, a P/E ratio of -5.67 and a beta of 1.49.
Hemogenyx Pharmaceuticals (LON:HEMO – Get Free Report) last announced its earnings results on Monday, September 28th. The company reported GBX (101.70) EPS for the quarter.
Hemogenyx Pharmaceuticals Company Profile
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Articles
- Five stocks we like better than Hemogenyx Pharmaceuticals
- Salesforce Fuels AI Engine With $5.66B Braze Buyout
- ServiceNow Orchestrates AI’s Next Act—Can Earnings Deliver?
- Drone Stocks Have Burned Investors—Are These 4 Different?
- 3M’s Legal Troubles Are Fading. Is the Best Part of Its Rally Still Ahead?
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
